Minimal residual disease
Advertisement
POLLUX and CASTOR: Daratumumab Combinations for MM Prolong MRD-Negativity
Rebecca AraujoOncology | March 31, 2023
Therapeutic regimens for multiple myeloma (MM) that use a combination of the anti-CD38 monoclonal antibody daratumumab ...
Read More
Real-World Efficacy of Minimal Residual Disease Diagnostics for Myeloma
Rebecca AraujoOncology | March 31, 2023
In a real-world study, minimal residual disease diagnostics for multiple myeloma (MM) were effective even in patients ...
Read More
Can an MRD Assay Better Predict DLBCL Disease Progression?
Kerri FitzgeraldASH Annual Meeting 2020 | April 6, 2023
Researchers assessed the use of a next-generation sequencing (NGS)-based minimal residual disease (MRD) assay for early ...
Read More
Using Minimal Residual Disease to Guide Treatment Choices and Detect Disease Recurrence in Patients With Multiple Myeloma and Acute Lymphocytic Leukemia
DocWire News EditorsOncology | April 28, 2023
Overview of Minimal Residual Disease ...
Read More
Advertisement
Advertisement
Advertisement
Latest News

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

April 15, 2025

Long-Term, Short-Term Inhaled Corticosteroid Exposure Outcomes in Chronic Obstructive Pulmonary Disease

April 15, 2025

Atrial Fibrillation Clinical Trials Suffer From Gender Disparities

April 15, 2025

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Editorial Policy

    Advertising

    Connect

    Contact Us

    eNewsletters

    Contribute

    Career Center

    Our Network

    MashupMD

    Blood Cancers Today

    Cancer Nursing Today

    GU Oncology Now

    Urban Health Today

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |